211 related articles for article (PubMed ID: 22929888)
1. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
3. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
4. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
[TBL] [Abstract][Full Text] [Related]
5. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck AR; Park Y; Brinton LA
Int J Cancer; 2013 Jan; 132(2):417-26. PubMed ID: 22553145
[TBL] [Abstract][Full Text] [Related]
6. Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort.
Brinton LA; Schwartz L; Spitz MR; Park Y; Hollenbeck AR; Gierach GL
Cancer Causes Control; 2012 Mar; 23(3):487-96. PubMed ID: 22367699
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of postmenopausal hormone use and ovarian cancer risk.
Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
[TBL] [Abstract][Full Text] [Related]
8. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
9. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
10. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen.
Hildebrand JS; Gapstur SM; Feigelson HS; Teras LR; Thun MJ; Patel AV
Int J Cancer; 2010 Dec; 127(12):2928-35. PubMed ID: 21351271
[TBL] [Abstract][Full Text] [Related]
12. Menopausal hormones and risk of ovarian cancer.
Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
[TBL] [Abstract][Full Text] [Related]
13. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
14. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone replacement therapy and risk of ovarian cancer.
Lacey JV; Mink PJ; Lubin JH; Sherman ME; Troisi R; Hartge P; Schatzkin A; Schairer C
JAMA; 2002 Jul; 288(3):334-41. PubMed ID: 12117398
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
17. Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women.
Sponholtz TR; Palmer JR; Rosenberg LA; Hatch EE; Adams-Campbell LL; Wise LA
Cancer Epidemiol Biomarkers Prev; 2018 May; 27(5):558-565. PubMed ID: 29475971
[No Abstract] [Full Text] [Related]
18. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.
Pearce CL; Chung K; Pike MC; Wu AH
Cancer; 2009 Feb; 115(3):531-9. PubMed ID: 19127543
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-progestin replacement therapy and endometrial cancer.
Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
[TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
Botteri E; Støer NC; Sakshaug S; Graff-Iversen S; Vangen S; Hofvind S; Ursin G; Weiderpass E
Int J Cancer; 2017 Nov; 141(9):1763-1770. PubMed ID: 28685818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
